Our findings demonstrate that: (1) the presented cART protocol improves neutrophil counts, suggesting that cART has some inhibition of FIV-induced myelosuppression; (2) FIV causes a greater Th2 immunophenotype compared to Th1, as evidenced by the increased proportion of CD4+CCR4+ cells; and (3) dolutegravir was the most stable and long-lasting, and it may be the most promising of the three cART drugs to treat FIV infection. The gene discussed is CD4; the disease is infection.